Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer - In correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase

Lung Cancer

Volumn 49, Issue 1, 2005, Pages 47-54

  Inoue, Kentarou ^a   Takao, Motoshi ^a   Watanabe, Fumiaki ^a   Tarukawa, Tomohito ^b   Shimamoto, Akira ^a   Kaneda, Masanori ^b   Sakai, Takashi ^b   Fukushima, Masakazu ^c   Shimpo, Hideto ^a   Yada, Isao ^a  

^a MIE UNIVERSITY   (Japan)

^b National Hospital Organization Mie Chuo Medical Center   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

4 Dihydroxypyridine; 5 Chloro 2; 5 Fluorouracil; Dihydropyrimidine dehydrogenase; Non small cell lung cancer; Thymidylate synthase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 20444363802     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.12.007     Document Type: Article

References (29)

1. G.J. Peters, C.L. van der Wilt, and B. van Triest Thymidylate synthase and drug resistance Eur J Cancer 31A 1995 1299 1305
2. D. Salonga, K.D. Danenberg, and M. Johnson Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res 6 2000 1322 1327
3. Y. Ishikawa, T. Kubota, and Y. Otani Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice Clin Cancer Res 5 1999 883 889
4. C.L. Huang, H. Yokomise, and S. Kobayashi Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU based chemotherapy Int J Oncol 17 2000 47 54
5. A. Beck, M.C. Etienne, and S. Cheradame A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil Eur J Cancer 30A 1994 1517 1522
6. M.C. Etienne, S. Cheradame, and J.L. Fischel Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activitym J Clin Oncol 13 1995 1663 1670
7. R.B. Diasio The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology Oncology 12 1998 23 27
8. P.M. Hoff, and R. Pazdur Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents Semin Oncol 26 1999 52 61
9. West Japan Study Group for Lung Cancer Surgery (WJSG) H. Wada, R. Miyata, and F. Tanaka Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegafur) in resected stage I-II NSCLC: a randomized clinical trial Eur J Cardiothorac Surg 15 1999 438 443
10. H. Kato, Y. Ichinose, and M. Ohta Japan Lung Cancer Research Group on postsurgical adjuvant chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med 350 17 2004 1713 1721
11. L.H. Sobin C.H. Wittekind UICC. Lung and pleural tumors, TNM classification of malignant tumors 5th ed. 1997 John Wiley & Sons New York 91 100
12. C.P. Spears, A.H. Shahinian, and R.G. Moran In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas Cancer Res 42 1982 450 456
13. H. Uetake, W. Ichikawa, and T. Takechi Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer Clin Cancer Res 5 1999 2836 2839
14. F.N.M. Naguib, M.H. el-Kouni, and S. Cha Enzymes of uracil catabolism in normal and neoplastic human tissues Cancer Res 45 1985 5405 5412
15. T. Takechi, J. Uchida, and A. Fujioka Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells Int J Oncol 11 1997 1041 1044
16. Y. Otake, F. Tanaka, and K. Yanagihara Expression of thymidylate synthase in human non-small cell lung cancer Jpn J Cancer Res 90 1999 1248 1253
17. H. Kobayashi, K. Tanisaka, and O. Doi An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures Int J Oncol 11 1997 449 455
18. T. Shirasaka, Y. Shimamoto, and H. Ohshimo Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 1996 548 557
19. S. Fujii, S. Kitano, and K. Ikenaka Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2- tetrahydrofuryl)-5-fluorouracil and level of 5-furuorouracil in rodents Gann 70 1979 209 214
20. M. Fukushima, M. Morita, and K. Ikeda Population study of expression of thymydirate synthase and dihidropyrimidine dehydrogenase inpatients with solid tumors Int J Mol Med 2 2003 839 844
21. M. Higashiyama, K. Kodama, and H. Yokouchi Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil Lung Cancer 34 2001 407 416
22. T. Shirasaka, K. Nakano, and T. Takechi Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 1996 2602 2606
23. M. Kawahara, K. Furuse, Y. Segawa S-1 Cooperative Study Group (Lung Cancer Working Group) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small cell lung cancer Br J Cancer 85 2001 939 943
24. W. Koizumi, M. Kurihara, S. Nakano for the S-1 Cooperative Gastric Cancer Study Group Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 2000 191 197
25. Y. Sakata, A. Ohtsu, and N. Horikoshi Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M Tegafur-0.4 M Gimeracil-1 M Otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1998 1715 1720
26. T. Takechi, A. Fujioka, and E. Matsushima Enhancement of the antitumor activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD) in human cancer cells Eur J Cancer 38 2002 1271 1277
27. M. Higashiyama, K. Kodama, and H. Yokouchi Cisplatin-based chemotherapy for postoperative recurrence in non-small lung cancer patients: relation of the in vitro chemosensitivity test to clinical response Oncol Rep 8 2001 279 283
28. T. Kikuchi, Y. Daigo, and T. Katagiri Expression of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs Oncogene 22 2003 2192 2205
29. M. Inaba, T. Tashiro, and Y. Ohnishi In vitro-in vivo correlation in anticancer drug sensitivity test using AUC-based concentrations and collagen gel droplet embedded culture Oncology 53 1996 250 257